Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effects of Dexmedetomidine on Clinical Outcomes and Renal Function After Cabg Publisher



Rahab M1 ; Heydarpour E2 ; Totonchi Z2 ; Kachoueian N3 ; Davani SZ4 ; Kiaei MM5 ; Mehrabanian MJ6 ; Panahi M7 ; Ahmadvand P1 ; Kharazani S7 ; Mortazian M8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Hazrat-E-Rasoul Akram Hospital, Iran University of Medical Science, Tehran, Iran
  2. 2. Rajaie Cardiovascular, Medical and Research Center, Tehran, Iran
  3. 3. Department of Cardiovascular Surgery, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Department of General Surgery, School of Medicine, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Anesthesiology, School of Medicine, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Anesthesiology, School of Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
  8. 8. AJA University of Medical Sciences, Tehran, Iran

Source: Journal of Cellular and Molecular Anesthesia Published:2021


Abstract

Background: This study was carried out to determine the effects of dexmedetomidine on clinical outcomes and renal function after coronary artery bypass grafting (CABG) to address the increased rate of CABG? and the importance of modification in stress responses and control of adverse effects on renal function and with the aim of cost reduction. Materials and Methods: This double-blind randomized clinical trial was carried out with the participation of 129 subjects under elective CABG in Rajaei Heart Center, Tehran, Iran in 2017. Patients were randomly assigned to four groups with simple randomization including one placebo (normal saline infusion) group and three dexmedetomidine groups; 0.5 µg/kg/h on CPB, 0.5 µg/kg/h in 24 hours, and 0.75 µg/kg/h in 24 hours. The blood pressure, blood urea nitrogen (BUN), serum creatinine, transfused blood volume, urine volume, and hemofiltration on pump and lactate were assessed at different time intervals. Results: Results showed more stability especially in central venous pressure (CVP) (p=0.001) and systolic blood pressure (p=0.006) in the groups receiving dexmedetomidine 0.75 µg/kg/h per 24 hours. But diastolic blood pressure and heart rate were the same across the groups (p>0.05). All other variables including hepatic and renal function tests were the same across the groups (P>0.05). Conclusion: Overall, according to the obtained results in the current study, it may be concluded that dexmedetomidine would have some promising effects on hemodynamic stability but there are no obvious renoprotective effects for this medication. © 2021 Journal of Cellular and Molecular Anesthesia. All rights reserved.